Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
dc.contributor.author | Tam, CS | |
dc.contributor.author | Opat, S | |
dc.contributor.author | Simpson, D | |
dc.contributor.author | Cull, G | |
dc.contributor.author | Munoz, J | |
dc.contributor.author | Phillips, TJ | |
dc.contributor.author | Kim, WS | |
dc.contributor.author | Rule, Simon | |
dc.contributor.author | Atwal, SK | |
dc.contributor.author | Wei, R | |
dc.contributor.author | Novotny, W | |
dc.contributor.author | Huang, J | |
dc.contributor.author | Wang, M | |
dc.contributor.author | Trotman, J | |
dc.date.accessioned | 2022-03-07T14:07:02Z | |
dc.date.issued | 2021-06-22 | |
dc.identifier.issn | 2473-9529 | |
dc.identifier.issn | 2473-9537 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/18906 | |
dc.description.abstract |
<jats:title>Abstract</jats:title> <jats:p>Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320 mg once daily (n = 18), or ≤160 mg total dose (n = 5). Herein, we report results for patients receiving a total daily dose of 320 mg (N = 32). Median study follow-up was 18.8 months. Eighteen patients discontinued treatment, 10 because of progressive disease and 8 because of adverse events (AEs); 1 AE (peripheral edema) was considered to be related to zanubrutinib treatment. The most common AEs were diarrhea (43.8%), contusion (37.5%), constipation (31.3%), and upper respiratory tract infection (31.3%). Infection was the most commonly reported AE of interest (18.8% of patients experienced grade ≥3 infection). At least 1 AE of grade ≥3 was reported in 59.4% of patients; grade ≥3 AEs that were reported in &gt;2 patients were anemia (12.5%), pneumonia (9.4%), and myalgia (9.4%). Overall response rate was 84%, with 25% achieving a complete response. Median duration of response was 18.5 months. Median progression-free survival (PFS) was 21.1 months. Zanubrutinib was well tolerated and demonstrated activity in patients with R/R MCL. The trial is registered at www.clinicaltrials.gov as #NCT02343120.</jats:p> | |
dc.format.extent | 2577-2585 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | en | |
dc.publisher | American Society of Hematology | |
dc.subject | Adult | |
dc.subject | Humans | |
dc.subject | Lymphoma, Mantle-Cell | |
dc.subject | Piperidines | |
dc.subject | Pyrazoles | |
dc.subject | Pyrimidines | |
dc.title | Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma | |
dc.type | journal-article | |
dc.type | Clinical Trial, Phase I | |
dc.type | Clinical Trial, Phase II | |
dc.type | Journal Article | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000664552400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 12 | |
plymouth.volume | 5 | |
plymouth.publication-status | Published | |
plymouth.journal | Blood Advances | |
dc.identifier.doi | 10.1182/bloodadvances.2020004074 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2021-04-08 | |
dc.rights.embargodate | 2022-3-8 | |
dc.identifier.eissn | 2473-9537 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1182/bloodadvances.2020004074 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021-06-22 | |
rioxxterms.type | Journal Article/Review |